HollyFrontier Corp. (HFC) Financials Nov 14, 2014, 4:29

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
HollyFrontier Corp. (HFC) Financials Nov 14, 2014, 4:29 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for HollyFrontier Corp.


Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 4.83B 8.32B 15.44B 20.19B 20.18B
Cost of Goods Sold (COGS) incl. D&A 4.34B 7.48B 13.58B 17.16B 18.84B
COGS excluding D&A 4.24B 7.37B 13.42B 16.91B 18.53B
Depreciation & Amortization Expense 98.75M 117.53M 159.71M 242.87M 303.45M
Depreciation 78.4M - 125M 182.9M 213.6M
Amortization of Intangibles 20.35M - 34.71M 59.97M 89.85M
Gross Income 497.51M 838.25M 1.85B 3.03B 1.34B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 60.34M 70.84M 93.61M 128.1M 127.96M
Research & Development 0 0 0 - 0
Other SG&A 60.34M 70.84M 93.61M 128.1M 127.96M
Other Operating Expense 356.86M 504.41M 0 0 0
Unusual Expense 3.13M 0 44.81M (33.34M) 6.61M
EBIT after Unusual Expense (3.13M) 0 (44.81M) 33.34M (6.61M)
Non Operating Income/Expense 0 0 0 (61.45M) 12.61M
Non-Operating Interest Income 5.05M 1.17M 1.28M 4.79M 5.52M
Equity in Affiliates (Pretax) 1.92M 2.39M 2.3M 2.92M (2.07M)
Interest Expense 40.35M 74.2M 78.32M 97.58M 65.11M
Gross Interest Expense 40.35M 74.2M 95.52M 106.68M 77.21M
Interest Capitalized 0 0 17.2M 9.1M 12.1M
Pretax Income 43.8M 192.36M 1.64B 2.79B 1.16B
Income Tax 7.46M 59.31M 581.99M 1.03B 391.58M
Income Tax - Current Domestic (27.14M) 35.47M 590.85M 932.55M 277.17M
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 37.52M 23.84M (8.86M) 95.41M 114.4M
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 2.92M 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 (2.75M)
Consolidated Net Income 36.34M 133.05M 1.06B 1.76B 765.07M
Minority Interest Expense 33.74M 29.09M 36.31M 32.86M 31.98M
Net Income 2.61M 103.96M 1.02B 1.73B 733.09M
Extraordinaries & Discontinued Operations 16.93M 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 12.5M 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 4.43M 0 0 0 0
Net Income After Extraordinaries 19.53M 103.96M 1.02B 1.73B 733.09M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 2.61M 103.96M 1.02B 1.73B 733.09M
EPS (Basic) 0.07 0.98 6.46 8.41 3.66
Basic Shares Outstanding 100.84M 106.44M 158.49M 205.29M 200.42M
EPS (Diluted) 0.07 0.97 6.42 8.38 3.64
Diluted Shares Outstanding 101.21M 107.22M 159.29M 206.18M 201.23M
EBITDA 179.06M 380.53M 1.92B 3.15B 1.52B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

M&A Source's 2026 Conference Tackles Deal-Making Drama

Updated Category News Views 130

High Stakes and Deep Insights Await in Houston Cracking the nut of lower-middle market transactions ain’t a walk in the park. M&A Source®'s Fall 2026 Conference is gearing up to address the very dramas that lurk behind the scenes. Kicking off November 2-4 at the opulent JW Marriott in Houston, Texas, the event is looking to assemble a heavyweight lineup of...

Continue Reading
Endava Faces Class Action: Investors Eye Their Next Move

Updated Category News Views 0

A Mess That Investors Can't Ignore If you're holding onto Endava plc shares, you've probably felt that gut-punch lately. Yeah, things are getting heated with a class action lawsuit alleging the company played fast and loose with its accounting practices. The complaint's about some shady dealings that may have thrown off investors' perceptions. The Core Allegations This...

Continue Reading
Astellas and Audax Forge $1.34B Immuno-Oncology Deal

Updated Category News Views 36

Big Moves in Immuno-Oncology: Astellas' Latest Bet You hear 'immuno-oncology,' you think breakthrough, right? Well, friends, that's what Astellas and Audax Biosciences are shooting for with their fresh handshake over DAX-044. On October 27, 2026, in Tokyo and Melbourne, the two outfits announced they're joining forces to bring this novel immunotherapy to the table. It's...

Continue Reading
OneQode & AdaniConneX Forge AI Path in India

Updated Category News Views 17

A Major Step Forward in AI Infrastructure When two heavyweights clash, you better believe folks are paying attention. OneQode’s deal with AdaniConneX is like a shot across the bow in the AI infrastructure arena. They’re not just dipping a toe in India’s tech waters; they’re diving headfirst with 14 MW of data center muscle right there in Siruseri Sipcot, Chennai....

Continue Reading
Lynk Pharmaceuticals' Zemprocitinib Shines in Phase III RA Trial

Updated Category News Views 48

A Deep Dive into Lynk Pharmaceuticals' Latest Revelation Lynk Pharmaceuticals just dropped a bombshell with their latest Phase III trial results for zemprocitinib. This selective JAK1 inhibitor seems to be bringing some serious game in the fight against moderate-to-severe rheumatoid arthritis (RA), especially for folks who haven't had much luck with biologics. The drug...

Continue Reading
Brightstar's Cash Pop Shakes Up Illinois Lottery Scene

Updated Category News Views 63

A New Twist in Illinois: Cash Pop's Arrival Here's something fresh off the press: the Illinois Lottery is now on the ride with Brightstar's Cash Pop. This patented game isn't just another number pick—it's an engaging draw-based game featuring hourly draws with price tags of $1, $2, $5, and $10. It's like clockwork, and trust me, it's more than just the usual spin....

Continue Reading
Etisalat Surges: Net Profit Soars 46% Amid Growth

Updated Category News Views 91

Etisalat's Stellar Performance: A Deeper Dive When a company like Etisalat drops news of a whopping 46% increase in net profit year-over-year, you sit up and pay attention. Those numbers aren’t just a flash in the pan; they're the result of some serious strategic maneuvers and ripe market conditions. Etisalat isn't resting on its laurels, and their latest financials...

Continue Reading
Amgen Declares Q4 Dividend Amidst Broad Horizons

Updated Category News Views 16

Amgen's Steady Dividend: A Testament to Stability Diving into the mess that is today's biotech market, Amgen (NASDAQ:AMGN) stands out like a beacon of stability with its recent dividend announcement. The Board's decision to dole out a $2.52 per share dividend for the fourth quarter of 2026 showcases confidence amidst both promising ventures and looming uncertainties....

Continue Reading
2026 World Laureates Forum Drives Science Forward

Updated Category News Views 78

A Meeting of Great Minds in Shanghai Alright, listen up. Shanghai's gearing up to be the nerve center for the 2026 World Laureates Forum (WLF), and it's seething with potential. This ain't your regular science fair; it's a lion's den of brainpower set to crack open the future of science and tech. With the heavy-hitters like Nobel and Turing laureates on the docket, you're...

Continue Reading
Mercado González Opens, Integrates Mexican Culture

Updated Category News Views 27

Dive into Mercado González's Cultural Opening Over in La Habra, Northgate González Market has just flung open the doors to its latest masterpiece: Mercado González. Picture this, a place where the mundanity of grocery shopping melds with a vibrant fiesta of Mexican cuisine, artisanry, and cultural vibes. They transformed an older store into something that commands not...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Exelon's Earnings: Insights and Future Potential

Updated Category News Views 142

Understanding Exelon's Upcoming Earnings Report Exelon Corporation (NASDAQ: EXC) is preparing to reveal its quarterly earnings in the near future. Investors are keenly awaiting the results, as they want insights into the company’s performance and projections for the following period. Analysts predict that Exelon will report an earnings per share (EPS) of $0.39,...

Continue Reading
Vallourec Invites Warrant Holders to General Meeting

Updated Category News Views 157

Vallourec Invites Warrant Holders to General Meeting Vallourec has announced a significant upcoming event for its warrant holders, also known as BSA. This meeting is set to take place soon, providing an opportunity for holders to engage with the company's future decisions. Details of the Meeting The general meeting will occur at the Vallourec headquarters, where the...

Continue Reading
Investigation Initiated for Molina Healthcare Investors Following Financial Reports

Updated Category News Views 246

Pomerantz LLP Begins Investigation on Behalf of Molina Investors Pomerantz LLP has embarked on an investigation focusing on the interests of investors in Molina Healthcare, Inc. (NYSE: MOH). This inquiry aims to ascertain whether Molina and certain executives may have been involved in any unlawful activities related to securities fraud. Key Financial Findings and Investor...

Continue Reading
How SymphonyAI's Insights Drive E-commerce Growth in Grocery

Updated Category News Views 159

Unlocking E-commerce Potential in Grocery Retail In a transformative announcement, SymphonyAI, a leader in predictive and generative AI SaaS products for enterprises, has unveiled groundbreaking insights from its annual grocery e-commerce study. This research indicates a noteworthy 8% growth opportunity for retailers leveraging AI-driven strategies in their connected...

Continue Reading
Exploring the Impact of Honda and Nissan's Potential Merger

Updated Category News Views 408

Honda and Nissan's Strategic Talks Honda (NYSE:HMC) and Nissan (OTC:NSANY) have entered discussions that may lead to a potential merger, a significant move reflecting the shifting landscape of Japan's automotive industry. As these two giants explore deeper ties, it marks a notable strategy to face the competition posed by Tesla and various Chinese car manufacturers....

Continue Reading